ClinicalTrials.gg
Not yet recruitingNCT06601517Updated Sep 23, 2024

A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.

A Phase 1 interventional study of Repaglinide and Atorvastatin in Healthy Adult Subject and Overweight Subject, sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-23.

Sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (part of Huadong Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Feb 2025, 1 year 9 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Overweight by Huadong Medicine Co., Ltd. — 7 open to participants now, 8 under way, 2 of them phase 3. Overweight · Huadong Medicine Co., Ltd..

Planned enrollment
9th of 10
30 · median 96
Started
2024
with 3 others
Phase 1
7 of 10
4 open now
Registered
4th of 10
by date

Among the 10 studies in Overweight by Huadong Medicine Co., Ltd., this one is the 9th largest by planned enrollment, is one of 4 that started in 2024, is one of 7 in phase 1, and was the 4th registered.

Overweight

3,613 studies on the registry are indexed under Overweight; 861 are open to participants now.

Browse Overweight studies →

Open to participants now

7 of the 10 studies in Overweight by Huadong Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 534 Overweight studies recruiting now, 159 (30%) set no upper age limit and 347 (65%) stop at 75 or younger; 64 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Overweight by Huadong Medicine Co., Ltd., or all of them as a file.
02

Study summary

The purpose of this study is to characterize the effect of HDM1002 on the PK of single dose of repaglinide, atorvastatin, digoxin and rosuvastatin in healthy adult subjects. The safety and tolerability of HDM1002 with repaglinide, atorvastatin, digoxin and rosuvastatin when given separately or together will also be evaluated.

03

Conditions studied

  • Healthy Adult Subject
  • Overweight Subject

Browse trials for

Keywords

  • HDM1002
  • Glucagon-Like Peptide-1 Receptor Agonists
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. According to the medical history, clinical laboratory test results, vital sign measurements, 12 lead results, and physical examination results during the screening period, the investigator considers the subject to be in good general health.
  2. Age range of 18-45 years old (including range), no limit to gender.
  3. Male subject weighed ≥50.0 kg, female subject weighed ≥45.0 kg, and a (BMI) within the range of 19.0 - 30.0 kg/m2 (including cut-off values).

Exclusion criteria

Exclusion Criteria:

  1. Subject has a history or family history of medullary thyroid cancer, thyroid C-cell hyperplasia, or multiple endocrine neoplasia type 2 (MEN2), or calcitonin≥50 ng/L during the screening period.
  2. History of chronic pancreatitis or an episode of acute pancreatitis within 3 months prior to screening.
  3. History of acute cholecystitis attack within 3 months prior to screening.
  4. Subject judged by investigator has dysphagia, diseases or conditions that affect gastric emptying, or affect the absorption of gastrointestinal nutrients, such as bariatric surgery or other gastrectomy, irritable bowel syndrome, dyspepsia, etc.
  5. History of previous surgery that will affect the absorption, distribution, metabolism, and excretion of drugs or plan to undergo surgery during the study period.
  6. During screening period, any abnormalities in physical examination, , laboratory tests, and vital signs which are of .
  7. Taken or planned to take any drug that effect liver enzyme or transporter activity within 28 days prior to taking the drug.
  8. History of clinically significant cardiovascular and cerebrovascular disease within 6 months prior to screening or at the time of admission.
  9. Presence of clinically significant ECG results judged by the investigator at screening.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    HDM1002 with Repaglinide, Atorvastatin, Digoxin and Rosuvastatin

    Period 1: Single dose of repaglinide, atorvastatin, digoxin and rosuvastatin Period 2: Once daily dose of HDM1002 Period 3: Single dose of repaglinide, atorvastatin, digoxin and rosuvastatin with once daily dose of HDM1002

    Drug: Repaglinide · Drug: Atorvastatin · Drug: Digoxin · Drug: Rosuvastatin · Drug: HDM1002

Interventions

06

What researchers measure

Primary outcomes

  1. AUC[0-∞]

    Pharmacokinetics (PK) parameter of repaglinide, atorvastatin, digoxin and rosuvastatin: Area under the curve from time 0 hour to ∞

    Time frame: Period 1 and Period 3: Day 1-Day 16

  2. AUC[0-t]

    PK parameter of repaglinide, atorvastatin, digoxin and rosuvastatin: Area under the curve from time 0 to t hour

    Time frame: Period 1 and Period 3: Day 1-Day 16

  3. Cmax

    PK parameter of repaglinide, atorvastatin, digoxin and rosuvastatin: Maximum observed concentration

    Time frame: Period 1 and Period 3: Day 1-Day 16

Secondary outcomes

  1. Tmax

    PK parameter of repaglinide, atorvastatin, digoxin and rosuvastatin: Time to maximum plasma concentration

    Time frame: Period 1 and Period 3: Day 1-Day 16

  2. t1/2

    PK parameter of repaglinide, atorvastatin, digoxin and rosuvastatin: Half life

    Time frame: Period 1 and Period 3: Day 1-Day 16

  3. CL/F

    PK parameter of repaglinide, atorvastatin, digoxin and rosuvastatin: Apparent Clearance

    Time frame: Period 1 and Period 3: Day 1-Day 16

  4. Vz/F

    PK parameter of repaglinide, atorvastatin, digoxin and rosuvastatin: Apparent volume of distribution

    Time frame: Period 1 and Period 3: Day 1-Day 16

  5. Adverse events (AEs)

    Number of subjects reporting AEs

    Time frame: Period 1 and Period 3: Day 1-Day 16, Period 2: Day 1-Day 35

07

Study locations

1 site
  • Peking University Third Hospital
    Beijing, China
    • Cui Cheng · Principal investigator
    • Dongyang Liu · Principal investigator
    • Xiaohong Wang · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2024; primary completion for Feb 2025, 4 months later.

Of 212 industry-sponsored phase 1 interventional studies under Overweight, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's planned 4 months is below that.

Counting every sponsor, half of 231 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2024
First posted
Sep 19, 2024
StartEst.
Oct 2024
Primary completionEst.
Feb 2025
CompletionEst.
Apr 2025
Last update
Sep 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06601517
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Oct 2024 (estimated)
Primary completion
Feb 2025 (estimated)
Completion
Apr 2025 (estimated)
Last update
Sep 23, 2024

Study contacts

Cheng Cui
Contact
cuicheng1226@163.com
+86-010 82266455

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Repaglinide · Atorvastatin · HDM1002

Start the discussion